Wealth Enhancement Advisory Services’s Pacira BioSciences PCRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$451K	Buy	12,387 +166	+1%	+$4.2K	﹤0.01%	2937
2026 Q2	$311K	Buy	12,221 +833	+7%	+$19.7K	﹤0.01%	3170
2026 Q1	$259K	Buy	11,388 +1,933	+20%	+$43K	﹤0.01%	2920
2025 Q4	$239K	Buy	9,455 +43	+0.5%	+$1.02K	﹤0.01%	3123
2025 Q3	$222K	Buy	9,412 +153	+2%	+$3.76K	﹤0.01%	3037
2025 Q2	$215K	Buy	+9,259	New	+$233K	﹤0.01%	2932

Other funds holding PCRX

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return

Gagnon Advisors New York $182M AUM 52.04% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Wealth Enhancement Advisory Services's PCRX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Pacira BioSciences (PCRX) stake by 1.4% in Q3 2026, buying an estimated $4.2K and bringing the position to 12,387 shares worth $451K. The position accounts for ﹤0.01% of the portfolio, ranked #2937.

Wealth Enhancement Advisory Services first reported a position in PCRX in Q2 2025 and has held it in 6 quarters since. 115 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

Wealth Enhancement Advisory Services held 12,387 shares of Pacira BioSciences worth $451K as of Q3 2026.
Wealth Enhancement Advisory Services bought 166 Pacira BioSciences shares in Q3 2026, an estimated $4.2K.
Pacira BioSciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #2937 holding.
Wealth Enhancement Advisory Services first reported a position in Pacira BioSciences in Q2 2025 and has held it in 6 quarters since.
115 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.